Xagenic to Participate in the 2015 Canaccord Genuity Medical Technologies & Diagnostics Forum

TORONTO--()--Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for use at the point of care, today announced that Timothy Still, President and CEO, and Ihor Boszko, Vice President of Business Development will be in attendance at the 2015 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 19th, 2015.

Logistical details for the company’s investor presentation include:

Presenter: Timothy Still
Date, Time: Thursday, November 19th, 2015; 10:00 a.m. – 10:20 a.m. ET; Track 6
Location: Westin New York Grand Central – 212 East 42nd Street, New York, NY, 10017

About Xagenic

Xagenic is a privately-held molecular diagnostics company developing the Xagenic X1™ platform, a revolutionary diagnostic system designed for use in a clinician’s office. The Xagenic X1 platform will allow users to perform lab-quality molecular diagnostic tests in the physician office. With a time-to-result of 20 minutes, the system is poised to transform the way healthcare is delivered. The Company is backed by Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation, BDC Capital and Qiagen. Xagenic was the 2014 Frost & Sullivan Point-of-Care Diagnostics New Product Innovation Leadership Award winner and the recipient of the 2015 Life Science Company of the Year award from Life Sciences Ontario. The Company is headquartered in Toronto with a San Francisco office. For more information, please visit www.xagenic.com.

Contacts

The Ruth Group
Media
Kirsten Thomas, 1-508-280-6592
kthomas@theruthgroup.com
or
Investors
Joseph Green, 1-646-536-7013
jgreen@theruthgroup.com